GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Enterprise Value

Kyorin Pharmaceutical Co (TSE:4569) Enterprise Value : 円107,018 Mil (As of May. 05, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kyorin Pharmaceutical Co's Enterprise Value is 円107,018 Mil. Kyorin Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円6,160 Mil. Therefore, Kyorin Pharmaceutical Co's EV-to-EBIT ratio for today is 17.37.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kyorin Pharmaceutical Co's Enterprise Value is 円107,018 Mil. Kyorin Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was 円6,160 Mil. Therefore, Kyorin Pharmaceutical Co's EV-to-EBITDA ratio for today is 17.37.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kyorin Pharmaceutical Co's Enterprise Value is 円107,018 Mil. Kyorin Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was 円119,830 Mil. Therefore, Kyorin Pharmaceutical Co's EV-to-Revenue ratio for today is 0.89.


Kyorin Pharmaceutical Co Enterprise Value Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Enterprise Value Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115,308.83 116,591.61 101,517.99 95,955.48 99,528.85

Kyorin Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100,832.27 99,528.85 102,588.13 99,526.44 103,636.94

Competitive Comparison of Kyorin Pharmaceutical Co's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Enterprise Value falls into.



Kyorin Pharmaceutical Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Kyorin Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Mar. 2023 is calculated as

Kyorin Pharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co  (TSE:4569) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Kyorin Pharmaceutical Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=107017.938/6160
=17.37

Kyorin Pharmaceutical Co's current Enterprise Value is 円107,018 Mil.
Kyorin Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,160 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Kyorin Pharmaceutical Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=107017.938/6160
=17.37

Kyorin Pharmaceutical Co's current Enterprise Value is 円107,018 Mil.
Kyorin Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,160 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Kyorin Pharmaceutical Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=107017.938/119830
=0.89

Kyorin Pharmaceutical Co's current Enterprise Value is 円107,018 Mil.
Kyorin Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円119,830 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co Enterprise Value Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines